61 related articles for article (PubMed ID: 12100629)
1. Loss of function of the tuberous sclerosis 2 tumor suppressor gene results in embryonic lethality characterized by disrupted neuroepithelial growth and development.
Rennebeck G; Kleymenova EV; Anderson R; Yeung RS; Artzt K; Walker CL
Proc Natl Acad Sci U S A; 1998 Dec; 95(26):15629-34. PubMed ID: 9861021
[TBL] [Abstract][Full Text] [Related]
2. Differential cellular expression of neurotrophins in cortical tubers of the tuberous sclerosis complex.
Kyin R; Hua Y; Baybis M; Scheithauer B; Kolson D; Uhlmann E; Gutmann D; Crino PB
Am J Pathol; 2001 Oct; 159(4):1541-54. PubMed ID: 11583980
[TBL] [Abstract][Full Text] [Related]
3. Gene therapy for tuberous sclerosis complex type 2 in a mouse model by delivery of AAV9 encoding a condensed form of tuberin.
Cheah PS; Prabhakar S; Yellen D; Beauchamp RL; Zhang X; Kasamatsu S; Bronson RT; Thiele EA; Kwiatkowski DJ; Stemmer-Rachamimov A; György B; Ling KH; Kaneki M; Tannous BA; Ramesh V; Maguire CA; Breakefield XO
Sci Adv; 2021 Jan; 7(2):. PubMed ID: 33523984
[TBL] [Abstract][Full Text] [Related]
4. Tuberous sclerosis complex: everything old is new again.
Ess KC
J Neurodev Disord; 2009 Jun; 1(2):141-9. PubMed ID: 21547713
[TBL] [Abstract][Full Text] [Related]
5. Recent Advances in Renal Tumors with TSC/mTOR Pathway Abnormalities in Patients with Tuberous Sclerosis Complex and in the Sporadic Setting.
Kapur P; Brugarolas J; Trpkov K
Cancers (Basel); 2023 Aug; 15(16):. PubMed ID: 37627070
[TBL] [Abstract][Full Text] [Related]
6. Distribution of shagreen patches and fibrous cephalic plaques in patients with tuberous sclerosis complex: A retrospective cohort study.
Takahashi A; Hattori S; Sakai E; Yang L; Katayama I; Fujimoto M; Wataya-Kaneda M
J Am Acad Dermatol; 2024 Apr; 90(4):849-852. PubMed ID: 38104779
[No Abstract] [Full Text] [Related]
7. Beyond Protein Synthesis; The Multifaceted Roles of Tuberin in Cell Cycle Regulation.
Fidalgo da Silva E; Fong J; Roye-Azar A; Nadi A; Drouillard C; Pillon A; Porter LA
Front Cell Dev Biol; 2021; 9():806521. PubMed ID: 35096832
[TBL] [Abstract][Full Text] [Related]
8. Incidental case finding of a 19-year-old woman with Tuberous Sclerosis Complex: A step-wise Multidisciplinary approach.
Ali S; Khan ST; Usman H; Khan AH; Douba Z; Ali M
Clin Case Rep; 2021 Oct; 9(10):e04933. PubMed ID: 34631098
[TBL] [Abstract][Full Text] [Related]
9. Correction: Understanding the impact of tuberous sclerosis complex: development and validation of the TSC-PROM.
Müller AR; Luijten MAJ; Haverman L; de Ranitz-Greven WL; Janssens P; Rietman AB; Hoopen LWT; de Graaff LCG; de Wit MC; Jansen AC; Gipson T; Capal JK; de Vries PJ; van Eeghen AM
BMC Med; 2023 Oct; 21(1):401. PubMed ID: 37872559
[No Abstract] [Full Text] [Related]
10. Molecular profiling of basal cell carcinomas in young patients.
Abi Karam M; Kourie HR; Jalkh N; Mehawej C; Kesrouani C; Haddad FG; Feghaly I; Chouery E; Tomb R
BMC Med Genomics; 2021 Jul; 14(1):187. PubMed ID: 34284772
[TBL] [Abstract][Full Text] [Related]
11. Polycystic kidney disease and chronic renal failure in tuberous sclerosis.
Dhakal M; Dhakal OP; Bhandari D
BMJ Case Rep; 2013 Oct; 2013():. PubMed ID: 24092520
[TBL] [Abstract][Full Text] [Related]
12. Topical rapamycin inhibits tuberous sclerosis tumor growth in a nude mouse model.
Rauktys A; Lee N; Lee L; Dabora SL
BMC Dermatol; 2008 Jan; 8():1. PubMed ID: 18226258
[TBL] [Abstract][Full Text] [Related]
13. Hypoxia-inducible factor-1alpha polymorphisms and TSC1/2 mutations are complementary in head and neck cancers.
Hebert C; Norris K; Parashar P; Ord RA; Nikitakis NG; Sauk JJ
Mol Cancer; 2006 Jan; 5():3. PubMed ID: 16412252
[TBL] [Abstract][Full Text] [Related]
14. Reduction of expression of tuberin, the tuberous-sclerosis-complex-gene-2 product in tuberous sclerosis complex associated connective tissue nevi and sporadic squamous and basal cell carcinomas.
Wienecke R; Klemm E; Karparti S; Swanson NA; Green AJ; DeClue JE
J Cutan Pathol; 2002 May; 29(5):287-90. PubMed ID: 12100629
[TBL] [Abstract][Full Text] [Related]
15. Localization of tuberous sclerosis 2 mRNA and its protein product tuberin in normal human brain and in cerebral lesions of patients with tuberous sclerosis.
Kerfoot C; Wienecke R; Menchine M; Emelin J; Maize JC; Welsh CT; Norman MG; DeClue JE; Vinters HV
Brain Pathol; 1996 Oct; 6(4):367-75. PubMed ID: 8944308
[TBL] [Abstract][Full Text] [Related]
16. Loss of expression of tuberin and hamartin in tuberous sclerosis complex-associated but not in sporadic angiofibromas.
Fackler I; DeClue JE; Rust H; Vu PA; Kutzner H; Rütten A; Kaddu S; Sander CA; Volkenandt M; Johnson MW; Vinters HV; Wienecke R
J Cutan Pathol; 2003 Mar; 30(3):174-7. PubMed ID: 12641776
[TBL] [Abstract][Full Text] [Related]
17. Identification of tuberin, the tuberous sclerosis-2 product. Tuberin possesses specific Rap1GAP activity.
Wienecke R; König A; DeClue JE
J Biol Chem; 1995 Jul; 270(27):16409-14. PubMed ID: 7608212
[TBL] [Abstract][Full Text] [Related]
18. The tuberous sclerosis complex genes in tumor development.
Mak BC; Yeung RS
Cancer Invest; 2004; 22(4):588-603. PubMed ID: 15565817
[TBL] [Abstract][Full Text] [Related]
19. Tuberous sclerosis complex and DNA repair.
Habib SL
Adv Exp Med Biol; 2010; 685():84-94. PubMed ID: 20687497
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
